Overview
Genxone is a laboratory specializing in next generation sequencing (NGS) and molecular diagnostics, utilizing nanopore sequencing technology developed by Oxford Nanopore Technologies. It offers a range of sequencing services, including metagenomic sequencing, 16s and/or ITS gene sequencing, and whole genome sequencing. Additionally, Genxone provides custom-designed analysis and bioinformatics services.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 5.76
- High
- PLN 5.78
- Low
- PLN 5.76
- Volume
- 4
- Avg. vol.
- 640.7
- Market cap
- PLN 19.10M
- P/E ratio
- –
- EPS
- -PLN 0.49
- Shares outstanding
- 3.3M
- 52-week
- PLN 5.04 – 6.20
- Dividend yield
- 17.30%
- Dividend
- PLN 1.00
- Ex dividend date
- Jun 16, 2022
- ISIN
- PLGENXN00013
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 153.16k | USD -94.27k | USD -88.87k |
| Q1 2026 | USD 132.63k | USD -145.60k | USD -139.65k |
| Q4 2025 | USD 230.29k | USD -57.76k | USD -49.22k |
| Q3 2025 | USD 127.83k | USD -169.01k | USD -161.73k |
Results for Q3 2026:Nov 12, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-11-17. Active
06 2490 0005 0000 4600 4782 8399- 25 2490 0005 0000 4600 6694 8891
- 37 2490 0005 0000 4600 3410 1856
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 11,896PLN 11,896 |
MSiG notices
6 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Jun 18, 2020 | Shareholders' meeting convened | |
| Feb 26, 2020 | Shareholders' meeting convened | |
| Dec 19, 2019 | Commercial Companies Code notice | |
| Nov 12, 2019 | Commercial Companies Code notice | |
| Nov 4, 2019 | Call to creditors |
Public aid
9 public aid cases recorded, with a total value of $1,118,093.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 21, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $10,556$10,556 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Sep 21, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,538$5,538 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,542$5,542 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2018-03-01 | Opracowanie innowacyjnego testu do diagnostyki ran pooperacyjnych z wykorzystaniem technologii sekwencjonowania nowej generacji NGS. | $912.0K$912,022 | Program Operacyjny Inteligentny Rozwój | |
| 2018-02-01 | Przygotowanie dokumentacji służącej pozyskaniu zewnętrznego finansowania dla spółki GENXONE Sp. z o.o. poprzez emisję akcji i ich debiut na rynku NewConnect GPW w Warszawie | $27,398$27,398 | Program Operacyjny Inteligentny Rozwój |
Tenders
7 tenders recorded as contractor, with a total value of $384,416.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Jun 25, 2026 | Kompleksowa usługa sekwencjonowania nowej generacji mikrobiomu | $66,647$66,647 | Narodowy Instytut Geriatrii,Reumatologii I Rehabilitacji Im. Prof. Dr Hab. Med. Eleonory Reicher | |
| Dec 3, 2025 | Sukcesywna dostawa odczynników chemicznych i materiałów mikrobiologicznych w ramach umowy ramowej dla Wojewódzkiej Stacji Sanitarno- Epidemiologicznej w Rzeszowie | $36,029$36,029 | Wojewódzka Stacja Sanitarno - Epidemiologiczna w Rzeszowie | |
| Oct 1, 2025 | Zakup systemu do analizy genów oporności bakterii na antybiotyki wraz z dzierżawą urządzenia do sekwencjonowania nowej generacji w technologii nanoporowej dla UCK. | $59,959$59,959 | Uniwersyteckie Centrum Kliniczne |
Public sector contracts
Genxone is the contractor in 3 public sector contracts, worth PLN 29.41k in total. They were signed with 3 public buyers.
| Public buyer | Value | |
|---|---|---|
| Uniwersytet Marii Curie-Skłodowskiej | PLN 2,358 | |
| Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan we Wrocławiu | PLN 9,500 | |
| Politechnika Łódzka | PLN 17,550 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
If one member of the management board has been appointed, that member is entitled to independently represent the company. If a multi-member management board has been appointed, the company shall be represented individually by each member of the management board.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| Eurxsp. z o.o. | $1,644,555.44 | eurx.com.pl | ||
| Zakład Genetyki Sądowejsp. z o.o. | $727,654.12 | dna-zgs.pl | ||
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| NanosanguisS.A. | $192,701.50 | nanosanguis.com | ||
| Nexbiosp. z o.o. | $186,582.40 | nexbio.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-07-19 | Share capital change (3,296,600.00 PLN → 3,304,820.00 PLN) | |
| 2023-07-27 | Share capital change (3,295,000.00 PLN → 3,296,600.00 PLN) | |
| 2020-06-15 | Share capital change (2,695,000.00 PLN → 3,295,000.00 PLN) | |
| 2019-09-17 | Share capital change (2,389,000.00 PLN → 2,695,000.00 PLN) | |
| 2019-06-19 | Share capital change (2,039,000.00 PLN → 2,389,000.00 PLN) |
FAQ
Last updated: 2026-07-09